Watson Pharmaceuticals, Inc. (NYSE: WPI) announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for Levonorgestrel and Ethinyl Estradiol Tablets, USP, 0.09 mg/0.02 mg, the generic equivalent to Pfizer's Lybrel?? tablets. Watson expects to launch the product shortly (see also U.S. Food and Drug Administration).
Lybrel?? had total U.S. sales of just under $12 million for the twelve months ending April 30, 2011, according to IMS Health. Lybrel?? tablets are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Keywords: FDA, Regulatory Actions, U.S. Food and Drug Administration, Watson Pharmaceuticals Inc.
This article was prepared by Women's Health Weekly editors from staff and other reports. Copyright 2011, Women's Health Weekly via NewsRx.com.
To see more of the NewsRx.com, or to subscribe, go to http://www.newsrx.com .
??? 2007 NewsRx.com. All Rights Reserved.;;??Copyright 2011, Women's Health Weekly via NewsRx.com